Boehringer Ingelheim names Gagandeep Singh as head of India pharma

Pharmaceutical company Boehringer Ingelheim said on Monday that it has appointed Gagandeep Singh as the head of its pharmaceutical business for the Indian market.

The company has appointed Singh as Managing Director and President of Human Pharma India effective July 10.

He will also join the board of directors of Boehringer Ingelheim India, the company said in a statement.

Boehringer Ingelheim has three business areas – Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

“Gagandeep’s passion for fostering a customer-centric culture and his experience across complex healthy ecosystems will be invaluable to the organization as we continue to strengthen our strategic and sustainability commitment to India,” Middle East, Turkey and Africa (META) Mohamed Tawil noted.

Singh joins Boehringer Ingelheim from AstraZeneca, where he was managing director of the India and Africa group.

He succeeds Fanny Manga, who transferred to Boehringer Ingelheim UK in February 2023.

During her transition, Sandeep Agrawal, Director of Finance and Administration, took on the additional responsibility of the Interim Managing Director.

First published: June 26, 2023 | 5:52 PM ist